Elite Pharmaceuticals, Inc.
ELTP · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $691,374 | $785,247 | $464,738 | $578,043 |
| - Cash | $26,617 | $21,738 | $11,315 | $8,293 |
| + Debt | $3,316 | $6,675 | $10,915 | $11,178 |
| Enterprise Value | $668,073 | $770,184 | $464,337 | $580,927 |
| Revenue | $36,322 | $40,211 | $31,996 | $14,364 |
| % Growth | -9.7% | 25.7% | 122.7% | – |
| Gross Profit | $14,073 | $27,226 | $17,295 | $6,119 |
| % Margin | 38.7% | 67.7% | 54.1% | 42.6% |
| EBITDA | $16,168 | $103 | $19,981 | -$10,086 |
| % Margin | 44.5% | 0.3% | 62.4% | -70.2% |
| Net Income | $13,702 | -$5,885 | $16,998 | -$10,892 |
| % Margin | 37.7% | -14.6% | 53.1% | -75.8% |
| EPS Diluted | 0.01 | -0.006 | 0.016 | -0.01 |
| % Growth | 281.8% | -134.6% | 255.9% | – |
| Operating Cash Flow | $5,104 | $14,776 | $3,918 | -$1,064 |
| Capital Expenditures | -$103 | -$218 | -$754 | $0 |
| Free Cash Flow | $5,001 | $14,558 | $3,164 | -$1,064 |